Affymetrix (NASDAQ:AFFX) announces that eBioscience, an Affymetrix business, and Binding Site Group Ltd. have entered into a multi-year distribution agreement. Under this agreement, The Binding Site has been granted the exclusive rights to distribute the eBioscience clinical flow cytometry reagents (ASR & CE marked) in the clinical care market, including hospitals and reference labs.

eBioscience, a world leader in immunology and oncology research reagents, offers one of the world's largest selections of antibodies, ELISAs, multiplex solutions, and proteins for immunology, oncology, cell biology, stem cell biology, and clinical markets.

The Binding Site is a world-wide in vitro diagnostic (IVD) supplier of special protein reagents and instruments, with a long history of success developing novel products to aid in the diagnosis and monitoring of monoclonal gammopathies such as multiple myeloma and other leukemia.

"Our best-in-class full ASR and CE designated immunology and oncology antibody portfolio is a natural complement to the expertise of The Binding Site," said Dara Grantham Wright, Senior Vice President & General Manager of the eBioscience business at Affymetrix. "Together we now provide an outstanding solution for clinicians to improve identification, interpretation, and management of clinical hematological malignancies. With this agreement, we strengthen our emphasis on addressing the needs of the growing cancer diagnostics market."

"Our vision is to lead the way in specialized medical diagnostics, as we do, for example, in multiple myeloma and immunodeficiency," said Charles de Rohan, Chief Executive of The Binding Site Group. "We are delighted to be joining forces with eBioscience, one of the most progressive providers of flow cytometry reagents. With our excellent direct sales and support coverage, we look forward to providing more clinical laboratories with this comprehensive portfolio of innovative products."

"This partnership broadens our cancer-based diagnostic portfolio and allows us to provide a more comprehensive product offering to our customers. We will be better positioned to meet the needs of clinicians by capitalizing on eBioscience's long history of quality flow cytometry reagents and our commitment to cancer diagnostics," said Doug Kurth, President of The Binding Site Inc.

The Binding Site started servicing customers in the United States on Dec. 1, 2014 and will start to service customers outside of the United States on Feb. 15, 2015.

About Binding Site Group Ltd.

Headquartered in Birmingham, UK, Binding Site is a Specialist Protein company committed to the research, development, manufacture and distribution of innovative, immunodiagnostic assays for the global laboratory market. By utilizing its specialized expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders.

Binding Site manufactures a wide range of innovative products for plasma protein analysis such as Freelite® and Hevylite ®, novel and highly significant tumor markers increasingly used for the diagnosis and monitoring of Multiple Myeloma, a cancer of cells in the bone marrow.

Binding Site is a market leader in the development of products for the investigation of Primary Immunodeficiency Disease (PID), disorders in which part of the body's immune system is missing or not functioning correctly.

Binding Site markets the SPAPLUS ®, a cost effective, reliable and easy to use analyzer offering a comprehensive menu of special proteins. The SPAPLUS complements the automated chemistry line as well as the special chemistry testing laboratory.

Binding Site is committed to disease state management and clinical practice guidelines. Binding Site's team of medical professionals have the exceptional expertise and practical experience to assist with technical and clinical education and training, from validation to implementation and beyond, giving clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients.

For more information about Binding Site, please visit

About eBioscience:

Established in San Diego, CA in 1999, eBioscience is a world leader in immunology and oncology flow cytometry reagents. eBioscience, was acquired by Affymetrix in 2012 and offers one of the world's largest selections of antibodies, ELISAs, and proteins for life science research and diagnostics.

eBioscience is an industry leader in reagent offerings for multicolor flow cytometry and immunoassay applications. We provide a comprehensive and innovative portfolio of reagents and kits for the immunology, oncology, cell biology, stem cell biology, and diagnostic markets.

For more information about eBioscience, please visit

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 65,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2013, and other SEC reports for subsequent quarterly periods.

Copyright Business Wire 2010